Biohaven Pharma (BHVN) Misses Q4 EPS by 11c

Biohaven Pharma (NYSE: BHVN) reported Q4 EPS of ($1.71), $0.11 worse than the analyst estimate of ($1.60).

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• Corporación América Airports S.A. (CAAP) Misses Q2 EPS by 18c
• Iridex Corp (IRIX) Misses Q2 EPS by 5c
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance